Formulation, pharmacokinetics and pharmacodynamics of topical microbicides
- PMID: 22306523
- PMCID: PMC3662244
- DOI: 10.1016/j.bpobgyn.2012.01.004
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides
Abstract
The development of safe topical microbicides that effectively prevent human immunodeficiency virus (HIV) infection is a major goal in curbing the human immunodeficiency virus pandemic. A number of past failures resulting from mucosal toxicity or lack of efficacy have informed the field. Products that caused toxicity to the female genital tract mucosa, and thereby increased the likelihood of HIV acquisition, included nonoxynol 9, cellulose sulfate, and C31 G vaginal gel Savvy. Topical products that were ineffective in preventing HIV infection include BufferGel, Carraguard, and PRO 2000. Antiretroviral drugs such as tenofovir and dapivirine formulated into microbicide products have shown promise, but there is much to learn about ideal product formulation and acceptability, and drug distribution and disposition (pharmacokinetics). Current formulations for water-soluble molecules include vaginally or rectally applied gels, vaginal rings, films and tablets. Dosing strategies (e.g. coitally dependent or independent) will be based on the pharmacokinetics of the active ingredient and the tolerance for less than perfect adherence.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Conflict of interest statement
None declared.
Similar articles
-
Topical microbicides for prevention of sexually transmitted infections.Cochrane Database Syst Rev. 2012 Jun 13;(6):CD007961. doi: 10.1002/14651858.CD007961.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2021 Mar 13;3:CD007961. doi: 10.1002/14651858.CD007961.pub3 PMID: 22696373 Updated. Review.
-
Vaginal deployment and tenofovir delivery by microbicide gels.Drug Deliv Transl Res. 2015 Jun;5(3):279-94. doi: 10.1007/s13346-015-0227-1. Drug Deliv Transl Res. 2015. PMID: 25874971 Free PMC article.
-
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.PLoS One. 2013;8(1):e55013. doi: 10.1371/journal.pone.0055013. Epub 2013 Jan 30. PLoS One. 2013. PMID: 23383037 Free PMC article. Clinical Trial.
-
AIDS: Drugs that prevent HIV infection.Nature. 2011 Jan 20;469(7330):306-7. doi: 10.1038/469306a. Nature. 2011. PMID: 21248832 No abstract available.
-
Clinical development of microbicides for the prevention of HIV infection.Curr Pharm Des. 2004;10(3):315-36. doi: 10.2174/1381612043386374. Curr Pharm Des. 2004. PMID: 14754390 Review.
Cited by
-
Gene Expression Profiling of Human Vaginal Cells In Vitro Discriminates Compounds with Pro-Inflammatory and Mucosa-Altering Properties: Novel Biomarkers for Preclinical Testing of HIV Microbicide Candidates.PLoS One. 2015 Jun 8;10(6):e0128557. doi: 10.1371/journal.pone.0128557. eCollection 2015. PLoS One. 2015. PMID: 26052926 Free PMC article.
-
Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research.AIDS Res Hum Retroviruses. 2013 Nov;29(11):1496-503. doi: 10.1089/aid.2013.0032. Epub 2013 May 17. AIDS Res Hum Retroviruses. 2013. PMID: 23607746 Free PMC article.
-
Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles.Sci Rep. 2016 May 6;6:25479. doi: 10.1038/srep25479. Sci Rep. 2016. PMID: 27151598 Free PMC article.
-
Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.Mol Pharm. 2014 May 5;11(5):1533-41. doi: 10.1021/mp4007024. Epub 2014 Apr 14. Mol Pharm. 2014. PMID: 24693866 Free PMC article.
-
Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.Antiviral Res. 2012 Dec;96(3):430-6. doi: 10.1016/j.antiviral.2012.09.015. Epub 2012 Oct 3. Antiviral Res. 2012. PMID: 23041201 Free PMC article.
References
-
- Garg S, Goldman D, Krumme M, et al. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res. 2010;885:S19–S29. - PubMed
-
- Malcolm RK, Edwards KL, Kiser P, et al. Advances in microbicide vaginal rings. Antiviral Res. 2010;885:S30–S39. - PubMed
-
- Morris GC, Lacey Charles JN. Microbicides and HIV prevention: lessons from the past, looking to the future. Curr Opin Infect Dis. 2010;23:57–63. - PubMed
-
- Van Damme L, Ramjee G, Alary M, et al. COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. Lancet. 2002;360:971–977. - PubMed
-
- Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for prevention of HIV transmission. N Engl J Med. 2008;359:463–472. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous